TNFRSF17 and plasma cell myeloma: In the ongoing UNIVERSAL trial of TCRKO/CD52KO HD-derived anti-BCMA CAR T cells (ALLO-715) in patients with multiple myeloma, there was evidence of CAR expansion in blood and encouraging clinical responses (NCT04093596) (46).